EVALUATION OF THE EFFICACY OF COSMETIC PRODUCT IN ADULTS SUBJECTS WITH MILD TO MODERATE ACNE

Inclusion Criteria: \- Sex: female and male; * Age: 20 years old and above; * Type: Caucasian; * Phototype: I to VI * At least 10 subjects per phototype; * At least 5 subjects with GEA 3 per phototype; * At least 2 males per phototype * Subjects with mild to moderate acne (GEA 2-3); * Subjects with at least 8 inflammatory lesions (full face); * Subjects at least 20 non inflammatory lesions (full face). Healthy subject; * Subject having given her/his free informed, web written consent; * Subject willing to adhere to the protocol and study procedures. Exclusion Criteria: * Concerns woman: Pregnant or nursing woman or woman planning to get pregnant during the study; * Cutaneous pathology on the studied zone other than acne (eczema etc.); * Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the acceptability and efficacy of the studied products (according to the investigator's appreciation); * Oral treatment of retinoids during the six previous months of the study; * Topical acne treatment since less than one month; * Acne with documented hormonal origin (e.g PCOS, hyperandrogenia of other origin). * Any change in hormonal treatment (including contraceptive) during the three previous months of the study or subject under Androcur®; * Subject under cyproterone-based or drospirenone medications (like Diane 35®, or Jasmine®, or Holgyème® or generic) treatments since less than six months; * Professional facial care during the previous month of the study; * Subject manipulating her acne lesions; * Subject with make-up on the day of the visit at the laboratory; * Excessive exposure to sunlight or UV-rays within the previous month; * Subject having undergone a surgery under general anesthesia within the previous month; * Subject enrolled in another clinical trial during the study period (concerns the studied zone); * Subject considered by the investigator to be likely not compliant to the protocol; * Subject enrolled in another clinical trial during the study period (concerns the studied zone); * Subject who does not meet the Ministry of Health guidelines for COVID-19 at time of the visit.